{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:58:24Z","timestamp":1761580704187,"version":"3.40.4"},"reference-count":18,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Despite high response rates with front-line platinum-based therapies, 80% of patients with metastatic urothelial cancer progress. Multiple agents and couplets have been investigated, but no standard second-line regimen exists. We conducted a phase II study to evaluate the efficacy and safety of docetaxel and oxaliplatin in metastatic urothelial cancer patients who had received prior platinum therapy. &lt;i&gt;Patients and Methods:&lt;\/i&gt; Patients with metastatic urothelial cancer, who had disease progression after platinum therapy, were treated with docetaxel 75 mg\/m&lt;sup&gt;2&lt;\/sup&gt; and oxaliplatin 85 mg\/m&lt;sup&gt;2&lt;\/sup&gt; every 3 weeks until disease progression or intolerable toxicity. &lt;i&gt;Results:&lt;\/i&gt; Between November 2004 and September 2005, 11 patients were enrolled. All patients had low or intermediate Bajorin risk. The median number of cycles administered was 2 (range 2\u20138). One patient achieved near complete response. Three patients experienced disease stabilization, resulting in a disease-control rate of 36%. Median overall survival was 7 months. The most common toxicities were fatigue and anemia (50%). &lt;i&gt;Conclusion:&lt;\/i&gt; Second-line docetaxel and oxaliplatin in metastatic urothelial cancer is safe and tolerable but did not achieve an appreciable response rate.<\/jats:p>","DOI":"10.1159\/000230695","type":"journal-article","created":{"date-parts":[[2009,7,24]],"date-time":"2009-07-24T11:20:14Z","timestamp":1248434414000},"page":"321-326","source":"Crossref","is-referenced-by-count":12,"title":["A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma"],"prefix":"10.1159","volume":"55","author":[{"given":"Sandy","family":"Srinivas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322%2FCA.2007.0010"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.23692"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159%2F000112311"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159%2F000140468"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fjnci%2F92.3.205"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819891215%2964%3A12%3C2448%3A%3AAID-CNCR2820641209%3E3.0.CO%3B2-7"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.10762"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819910315%2967%3A6%3C1525%3A%3AAID-CNCR2820670611%3E3.0.CO%3B2-8"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159%2F000055202"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038%2Fsj.bjc.6603118"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0022-5347%2801%2965614-3"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016%2FS0959-8049%2898%2900030-6"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.03.6699"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.20.4.937"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdm160"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdl057"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1081%2FCNV-120003536"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdl435"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/230695","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/230695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T22:07:12Z","timestamp":1745446032000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000230695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000230695","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2009]]}}}